Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.

Davidson BA, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, Previs RA, Salinaro J, Salani R, Moore K, Secord AA.

Gynecol Oncol. 2019 Mar;152(3):554-559. doi: 10.1016/j.ygyno.2018.12.011. Epub 2018 Dec 14.

PMID:
30558972
2.

Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.

Billingsley CC, Cohn DE, Crim AK, Li Q, O'Malley DM, Havrilesky LJ.

Cancer Treat Res Commun. 2018;14:21-25. doi: 10.1016/j.ctarc.2017.11.003. Epub 2017 Nov 10.

PMID:
30104004
3.

Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.

Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, Mukherjee P, Moore KN, Cao L, Branstrom A, Weetall M, Baird J, Bhattacharya R.

Mol Cancer Ther. 2018 Oct;17(10):2136-2143. doi: 10.1158/1535-7163.MCT-17-1192. Epub 2018 Jul 19.

4.

Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.

Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, Cao L, Sydorenko N, Baiazitov R, Moon YC, Dumble M, Davis T, Bhattacharya R.

Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.

5.

Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.

El-Matary W, Dykes DMH, Bauman L, Elkadri A, Carroll MW, Izaguirre MR, deBruyn J, Samson CM, Crim AM, Ali S, Grossman A.

Inflamm Bowel Dis. 2017 Dec;23(12):2104-2108. doi: 10.1097/MIB.0000000000001259.

6.

Factors influencing clinical trial enrollment among ovarian cancer patients.

Greenwade MM, Moore KN, Gillen JM, Ding K, Rowland MR, Crim AK, Kleis B, Gunderson CC.

Gynecol Oncol. 2017 Sep;146(3):465-469. doi: 10.1016/j.ygyno.2017.06.035. Epub 2017 Jul 6.

PMID:
28689668
7.

Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.

Crim A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, Gillen J, Ding K, Moore K, Gunderson C.

Gynecol Oncol. 2017 Aug;146(2):268-272. doi: 10.1016/j.ygyno.2017.05.032. Epub 2017 Jun 2.

PMID:
28583323
8.

Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.

Gillen J, Gunderson C, Greenwade M, Rowland M, Ruskin R, Ding K, Crim A, Walter A, White E, Moore K.

Gynecol Oncol. 2017 Apr;145(1):32-36. doi: 10.1016/j.ygyno.2016.12.023. Epub 2017 Jan 10.

PMID:
28087143
9.
10.

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.

Billingsley CC, Jacobson SN, Crafton SM, Crim AK, Li Q, Hade EM, Cohn DE, Fowler JM, Copeland LJ, Salani R, Backes FJ, O'Malley DM.

Int J Gynecol Cancer. 2015 Sep;25(7):1331-6. doi: 10.1097/IGC.0000000000000487.

PMID:
26067861
11.

Recruiting Practice-based Research Network (PBRN) physicians to be research participants: lessons learned from the North Texas (NorTex) needs assessment study.

Fulda KG, Hahn KA, Young RA, Marshall JD, Moore BJ, Espinoza AM, Beltran NM, McFadden P, Crim AD, Cardarelli R.

J Am Board Fam Med. 2011 Sep-Oct;24(5):610-5. doi: 10.3122/jabfm.2011.05.110075.

12.

Rapid in vitro method for determining cytotoxicity of antitumor agents.

Buskirk HH, Crim A, Van Giessen GJ, Petering HG.

J Natl Cancer Inst. 1973 Jul;51(1):135-8. No abstract available.

PMID:
4720868

Supplemental Content

Support Center